ResQ Pharma develops LipidRescue Therapy (LRT), a lipid emulsion treatment intended to reduce life‑threatening toxicity from overdoses of certain lipophilic drugs. The company highlights that the American Heart Association and American College of Medical Toxicology view LRT as a reasonable consideration for serious local anesthetic toxicity. ResQ scheduled a meeting with the U.S. Food and Drug Administration on September 29, 2016 to discuss an application for LRT as a treatment for local anesthetic systemic toxicity (LAST). The company has filed Orphan Drug Designation applications in both the U.S. and the European Union. ResQ cites CDC data on drug‑overdose mortality to frame the clinical need for its therapy. Organizationally, ResQ notes membership in several incubators and programs and that DLA Piper provided legal counsel for its financing.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Sep 2016